



February 10, 2025



National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 543524

**Sub: Integrated Filing (Financial) for the quarter and nine months ended
December 31, 2024.**

Dear Sir/ Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are herewith submitting the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

This will also be hosted on the Company's website, at <https://www.rainbowhospitals.in/>

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

Shreya Mitra
Company Secretary and Compliance Officer

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034.

Corporate Office: 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills, Hyderabad, Telangana - 500034.

Hyderabad: Banjara Hills - 040-22334455 | Secunderabad - 040-42462200 | Kondapur IP - 040-42462400 | Kondapur OP - 040-42462100
Hyder Nagar - 040-42462300 | L B Nagar - 040-71111333 | Financial District - 040-69313233 | Himayat Nagar - 040-48873000

Vijayawada: Currency Nagar - 0866-6669666 | Governorpet - 0866-6650250

Chennai: Guindy - 044-40122444 | Sholinganallur - 044-69659000 | Anna Nagar - 044-69289928

Bengaluru: Marathahalli - 080-42412345 | Bannerghatta Road - 080-25512345 | Hebbal - 080-35061555 | Sarjapur - 080-62282999

Delhi: Malviya Nagar - 011-66888866 | **Visakhapatnam:** Health City - 0891-3501601 | Siripuram - 0891-3501555

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Rainbow Children's Medicare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Rainbow Children's Medicare Limited** (the "Company") for the quarter ended 31 December 2024 and year to date from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava
Partner

Membership No.: 504777

UDIN: 25504777BMOCCLM6614

Place: Hyderabad

Date: 09 February 2025



Rainbow Children's Medicare Limited


CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034

Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Standalone Financial Results for the quarter and year to date ended 31 December 2024

Particulars	(Rs. in Million except per share data)					
	Quarter ended			Year to date ended		Year ended
	31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	3,815.65	4,039.25	3,217.90	11,005.12	9,108.05	12,365.62
b. Other income	128.48	107.24	82.41	350.54	247.13	369.48
Total income	3,944.13	4,146.49	3,300.31	11,355.66	9,355.18	12,735.10
2. Expenses						
a. Cost of materials consumed	519.61	521.96	408.32	1,454.18	1,170.63	1,571.27
b. Employee benefits expense	471.95	515.11	412.76	1,457.61	1,213.32	1,687.09
c. Finance costs	173.51	173.89	135.19	521.79	399.53	560.66
d. Depreciation and amortisation expense	335.39	332.23	259.34	992.00	745.83	1,051.51
e. Professional fees to doctors	891.50	899.84	730.52	2,589.10	2,138.16	2,877.30
f. Other expenses	631.04	667.50	528.73	1,867.61	1,479.78	2,095.10
Total expenses	3,023.00	3,110.53	2,474.86	8,882.29	7,147.25	9,842.93
3. Profit before tax [1-2]	921.13	1,035.96	825.45	2,473.37	2,207.93	2,892.17
4. Tax expenses						
a. Current tax	223.62	291.22	228.59	666.22	608.06	745.43
b. Deferred tax expense/(credit)	7.91	(25.40)	(14.55)	(39.85)	(44.68)	(2.17)
c. Adjustment of tax relating to earlier years	19.85	(3.30)	-	16.55	-	-
Total tax expense	251.38	262.52	214.04	642.92	563.38	743.26
5. Profit after tax [3-4]	669.75	773.44	611.41	1,830.45	1,644.55	2,148.91
6. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement (loss)/gain on defined benefit obligation	(50.05)	7.40	1.72	(41.45)	5.15	17.21
b. Income tax effect	12.60	(1.87)	(0.43)	10.43	(1.30)	(4.33)
Other comprehensive income, net of tax	(37.45)	5.53	1.29	(31.02)	3.85	12.88
7. Total comprehensive income [5+6]	632.30	778.97	612.70	1,799.43	1,648.40	2,161.79
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.52	1,015.52	1,015.02	1,015.52	1,015.02	1,015.02
9. Other equity						11,837.49
10. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	6.60	7.62	6.03	18.03	16.20	21.17
b. Diluted (Rs)	6.60	7.62	6.03	18.03	16.20	21.17
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 February 2025. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results.
- During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.
The Company had received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO expenses Rs. 138.60 million have been adjusted with securities premium as per the Companies Act , 2013.

Details of utilisation of IPO proceeds:

Objects of the issue	Amount as proposed in offer document (A)	Amount to be spent as per offer document up to 31 March 2025* (B)	Amount to be spent as per offer document for the year 2024-25 (C)	Status as at 31 December 2024 (Rs. in Million)	
				Utilisation up to 31 December 2024 (D)	Unspent balance as at 31 December 2024 (E) = (B) - (D)
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	1,700.00	200.00	1,583.71	116.29
General corporate purposes *	561.40	576.10	-	576.10	-
Total	2,661.40	2,676.10	200.00	2,559.81	116.29

* During the financial year 2023-24, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per the Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 had approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table above. After this change, amount to be utilised for General corporate purposes is Rs. 576.10 million.

Net IPO proceeds which are unutilised as at 31 December 2024 amounting to Rs. 116.29 million (column E) have been temporarily invested in fixed deposits and held in current account with banks.

- The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- The unaudited standalone financial results for the quarter and year to date ended 31 December 2024, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 09 February 2025

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Rainbow Children's Medicare Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2024 and year to date from 01 April 2024 to 31 December 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company:

Rainbow Children's Medicare Limited

Subsidiaries:

- a) Rainbow Speciality Hospitals Private Limited
- b) Rosewalk Healthcare Private Limited
- c) Rainbow C R O Private Limited
- d) Rainbow Fertility Private Limited
- e) Rainbow Children's Hospital Private Limited
- f) Rainbow Women & Children's Hospital Private Limited



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes unaudited interim financial results in respect of 6 subsidiaries, whose interim financial results reflect total revenues of Rs 178.31 million and Rs 529.51 million, total net profit after tax of Rs 19.69 million and Rs 46.29 million, total comprehensive income of Rs 19.81 million and Rs 46.65 million, for the quarter ended 31 December 2024 and the period ended on that date respectively.

The unaudited interim financial results of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the financial results certified by the Management.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


per Atin Bhargava

Partner

Membership No.: 504777



UDIN: 25504777BMOCLN4550

Place: Hyderabad

Date: 09 February 2025

Statement of Unaudited Consolidated Financial Results for the quarter and year to date ended 31 December 2024

(Rs. in Million except per share data)

Particulars	Quarter ended			Year to date ended		Year ended
	31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	3,980.82	4,174.60	3,359.58	11,457.59	9,557.98	12,969.00
b. Other income	132.74	112.73	86.09	364.81	242.87	370.64
Total income	4,113.56	4,287.33	3,445.67	11,822.40	9,800.85	13,339.64
2. Expenses						
a. Cost of materials consumed	537.28	516.72	426.97	1,478.79	1,233.41	1,652.80
b. Employee benefits expense	493.06	537.47	434.25	1,520.51	1,277.55	1,761.70
c. Finance costs	180.70	181.02	142.62	543.34	422.07	590.54
d. Depreciation and amortisation expense	352.34	349.00	276.60	1,042.77	797.84	1,120.82
e. Professional fees to doctors	943.70	952.26	772.11	2,745.60	2,265.35	3,053.66
f. Other expenses	663.21	697.34	545.47	1,961.07	1,548.24	2,211.99
Total expenses	3,170.29	3,233.81	2,598.02	9,292.08	7,544.46	10,391.51
3. Profit before tax [1-2]	943.27	1,053.52	847.65	2,530.32	2,256.39	2,948.13
4. Tax expenses						
a. Current tax	228.10	293.94	235.67	678.57	629.96	770.39
b. Deferred tax expense/(credit)	5.91	(27.17)	(13.75)	(41.54)	(45.79)	(5.13)
c. Adjustment of tax relating to earlier years	19.85	(3.30)	-	16.55	-	-
Total tax expense	253.86	263.47	221.92	653.58	584.17	765.26
5. Profit after tax [3-4]	689.41	790.05	625.73	1,876.74	1,672.22	2,182.87
6. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement (loss)/gain on defined benefit obligation	(49.92)	7.51	1.90	(41.07)	5.71	17.70
b. Income tax effect	12.59	(1.87)	(0.44)	10.41	(1.32)	(4.36)
Other comprehensive income, net of tax	(37.33)	5.64	1.46	(30.66)	4.39	13.34
7. Total comprehensive income [5+6]	652.08	795.69	627.19	1,846.08	1,676.61	2,196.21
Profit after tax attributable to						
Owners of the Company	686.87	788.69	621.25	1,870.89	1,660.28	2,170.01
Non-controlling interests	2.54	1.36	4.48	5.85	11.94	12.86
Profit after tax	689.41	790.05	625.73	1,876.74	1,672.22	2,182.87
Other comprehensive income attributable to						
Owners of the Company	(37.33)	5.63	1.46	(30.67)	4.38	13.33
Non-controlling interests	0.00	0.01	(0.00)	0.01	0.01	0.01
Other comprehensive income	(37.33)	5.64	1.46	(30.66)	4.39	13.34
Total comprehensive income attributable to						
Owners of the Company	649.54	794.32	622.71	1,840.22	1,664.66	2,183.34
Non-controlling interests	2.54	1.37	4.48	5.86	11.95	12.87
Total comprehensive income	652.08	795.69	627.19	1,846.08	1,676.61	2,196.21
8. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.52	1,015.52	1,015.02	1,015.52	1,015.02	1,015.02
9. Other equity						11,574.25
10. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	6.76	7.77	6.12	18.43	16.36	21.38
b. Diluted (Rs)	6.76	7.77	6.12	18.43	16.36	21.38
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 February 2025. The Statutory Auditors have carried out a limited review on the unaudited consolidated financial results.
- 2 During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.

The Company had received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between the Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million have been adjusted with securities premium as per Companies Act, 2013.

Details of utilisation of IPO proceeds:

(Rs. in Million)

Objects of the issue	Amount as proposed in offer document (A)	Amount to be spent as per offer document up to 31 March 2025* (B)	Amount to be spent as per offer document for the year 2024-25 (C)	Status as at 31 December 2024	
				Utilisation up to 31 December 2024 (D)	Unspent balance as at 31 December 2024 (E) = (B) - (D)
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new	1,700.00	1,700.00	200.00	1,583.71	116.29
General corporate purposes*	561.40	576.10	-	576.10	-
Total	2,661.40	2,676.10	200.00	2,559.81	116.29

* During the financial year 2023-24, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per the Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 had approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table above. After this change, amount to be utilised for General corporate purposes is Rs. 576.10 million.

Net IPO proceeds which are unutilised as at 31 December 2024 amounting to Rs. 116.29 million (column E) have been temporarily invested in fixed deposits and held in current account with banks.

- 3 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 4 The consolidated financial results for the quarter and year to date ended 31 December 2024, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 5 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited and Rainbow Children's Hospital Private Limited.

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited




Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 09 February 2025

B. Statement of Deviation/ Variation in utilisation of funds raised in IPO of the Company

Name of listed entity	Rainbow Children's Medicare Limited
Mode of Fund Raising	Public Issue/ Rights Issues/ Preferential Issues/ QIP/ Others
Date of Raising Funds	<ul style="list-style-type: none"> BID/ Offer Opened from April 27, 2022 to April 29, 2022 Allotment of equity shares on May 6, 2022 Listed on May 10, 2022
Amount Raised	Offer for sale: INR 13,008.49 Million Fresh Issue: INR 2,800 Million Total Issue: INR 15,808.49 Million
Report filed for Quarter ended	December 31, 2024
Monitoring Agency	Applicable/ Not Applicable
Monitoring Agency Name, if applicable	HDFC Bank Limited
Is there a Deviation/ Variation in use of funds raised	Yes/ No
If yes, whether the same is pursuant to change in Not Applicable terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/ Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Objects for which funds have been raised and where there has been a deviation, in the following table
(INR in Millions)

Original Objects	Modified Object, if any	Original Allocation*	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
1) Early redemption of Non-Convertible Debentures (NCDs) issued by our Company to CDC Emerging Markets Limited ("CDCEML"), one of our Group Companies, in full	N.A	400.00	N.A	400.00	N.A	NCD repaid on June 9, 2022.

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034.

Corporate Office: 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills, Hyderabad, Telangana - 500034.


Hyderabad: Banjara Hills - 040-22334455 | Secunderabad - 040-42462200 | Kondapur IP - 040-42462400 | Kondapur OP - 040-42462100
Hyder Nagar - 040-42462300 | L B Nagar - 040-71111333 | Financial District - 040-69313233 | Himayat Nagar - 040-48873000

Vijayawada: Currency Nagar - 0866-6669666 | Governorpet - 0866-6650250

Chennai: Guindy - 044-40122444 | Sholinganallur - 044-69659000 | Anna Nagar - 044-69289928

Bengaluru: Marathahalli - 080-42412345 | Bannerghatta Road - 080-25512345 | Hebbal - 080-35061555 | Sarjapur - 080-62282999

Delhi: Malviya Nagar - 011-66888866 | **Visakhapatnam:** Health City - 0891-3501601 | Siripuram - 0891-3501555



2) Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	N.A	1,700.00	N.A	1,583.71	N.A	N.A
3) General Corporate purposes	N.A	561.40	576.10	576.10	N.A	N.A

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
 (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
 (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

* The amount of original allocation represents the amount raised through Fresh Issue (net of offer expenses as mentioned in the Prospectus dated May 2, 2022)

For Rainbow Children's Medicare Limited

Vikas Maheshwari

Vikas Maheshwari
Chief Financial Officer



Date: February 9, 2025
Place: Hyderabad

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034.

Corporate Office: 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills, Hyderabad, Telangana - 500034.

Hyderabad: Banjara Hills - 040-22334455 | Secunderabad - 040-42462200 | Kondapur IP - 040-42462400 | Kondapur OP - 040-42462100
 Hyder Nagar - 040-42462300 | L B Nagar - 040-71111333 | Financial District - 040-69313233 | Himayat Nagar - 040-48873000

Vijayawada: Currency Nagar - 0866-6669666 | Governorpet - 0866-6650250

Chennai: Guindy - 044-40122444 | Sholinganallur - 044-69659000 | Anna Nagar - 044-69289928

Bengaluru: Marathahalli - 080-42412345 | Bannerghatta Road - 080-25512345 | Hebbal - 080-35061555 | Sarjapur - 080-62282999

Delhi: Malviya Nagar - 011-66888866 | **Visakhapatnam:** Health City - 0891-3501601 | Siripuram - 0891-3501555

- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – **Not Applicable, No default**
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter) - **Not applicable**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not applicable**

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034.

Corporate Office: 8-2-19/1/A, Daulet Arcade, Karvy Lane, Road No. 11, Banjara Hills, Hyderabad, Telangana - 500034.

Hyderabad: Banjara Hills - 040-22334455 | Secunderabad - 040-42462200 | Kondapur IP - 040-42462400 | Kondapur OP - 040-42462100
Hyder Nagar - 040-42462300 | L B Nagar - 040-71111333 | Financial District - 040-69313233 | Himayat Nagar - 040-48873000

Vijayawada: Currency Nagar - 0866-6669666 | Governorpet - 0866-6650250

Chennai: Guindy - 044-40122444 | Sholinganallur - 044-69659000 | Anna Nagar - 044-69289928

Bengaluru: Marathahalli - 080-42412345 | Bannerghatta Road - 080-25512345 | Hebbal - 080-35061555 | Sarjapur - 080-62282999

Delhi: Malviya Nagar - 011-66888866 | **Visakhapatnam:** Health City - 0891-3501601 | Siripuram - 0891-3501555